🇺🇸 FDA
Pipeline program

Cretostimogene Grenadenorepvec

CG3002S

Phase 3 mab active

Quick answer

Cretostimogene Grenadenorepvec for Non Muscle Invasive Bladder Cancer is a Phase 3 program (mab) at CG Oncology with 2 ClinicalTrials.gov record(s).

Program details

Company
CG Oncology
Indication
Non Muscle Invasive Bladder Cancer
Phase
Phase 3
Modality
mab
Status
active

Clinical trials